实验方案(Protocols)

Recombinant Human ATP1A2 Protein: Handling & Usage Protocol

Recombinant Human ATP1A2 Protein is a research-grade recombinant form of the alpha-2 catalytic subunit of Na+/K+-ATPase, produced for use in enzymatic activity assays, binding studies, and investigation of neurological disorders such as familial hemiplegic migraine.

Product Name
Recombinant Human ATP1A2 Protein
SKU
rp369942
Protein Function
Catalytic alpha-2 subunit of Na+/K+-ATPase; maintains electrochemical gradients across plasma membranes via ATP-driven ion exchange
Primary Research Applications
Enzymatic activity assays, protein–protein interaction studies, drug screening, neurological disease modeling
Recommended Storage
-80 °C for long-term storage; avoid repeated freeze-thaw cycles
Species Origin
Human (Homo sapiens)

Background: ATP1A2 and Na+/K+-ATPase Biology

The ATP1A2 gene encodes the alpha-2 isoform of the Na+/K+-ATPase catalytic subunit, a P-type ATPase responsible for maintaining sodium and potassium gradients across the plasma membrane. This ion pump exchanges three intracellular Na+ ions for two extracellular K+ ions per ATP hydrolysis cycle, generating the electrochemical gradients essential for membrane potential, cell volume regulation, and secondary active transport.

The alpha-2 subunit is predominantly expressed in astrocytes, cardiac muscle, and skeletal muscle. In the central nervous system, ATP1A2 plays a critical role in clearing extracellular K+ and glutamate following neuronal activity. Loss-of-function mutations in ATP1A2 are associated with Familial Hemiplegic Migraine type 2 (FHM2), underscoring its importance as a research target in neurological and cardiovascular disease contexts.

Reconstitution and Preparation Protocol

Follow these steps carefully to ensure protein integrity and activity upon reconstitution:

  1. Equilibrate to room temperature: Allow the lyophilized vial to equilibrate to room temperature (18–25 °C) for 10–15 minutes before opening to minimize condensation-related dilution.
  2. Prepare reconstitution buffer: Use sterile, ultrapure water or a phosphate-buffered saline (PBS, pH 7.4) supplemented with a carrier protein (e.g., 0.1% BSA) to stabilize the recombinant protein. Consult the Certificate of Analysis (CoA) for the specific buffer recommended for this lot.
  3. Add reconstitution buffer: Add the recommended volume of buffer gently along the inside wall of the vial. Do not vortex. Allow the lyophilized cake to dissolve by gentle swirling or rotation for 5–10 minutes at room temperature.
  4. Verify complete dissolution: The solution should be clear with no visible particulates. If particulates are observed, centrifuge briefly at low speed (≤1,000 × g) and use the supernatant.
  5. Aliquot immediately: Divide the reconstituted protein into single-use aliquots (typically 5–20 µL) to avoid repeated freeze-thaw cycles that degrade activity.

Note: The specific reconstitution volume and target protein concentration are provided on the product CoA. Always refer to the CoA supplied with your specific lot.

Storage, Stability, and Handling Guidelines

Proper storage is essential to maintain the biological activity of Recombinant Human ATP1A2 Protein:

  • Short-term storage (≤1 week): Store at 4 °C. Keep the protein in a buffered solution supplemented with a carrier protein to maintain stability.
  • Long-term storage: Store aliquots at -80 °C. Under recommended conditions, the protein is expected to remain stable for up to 12 months from the date of receipt when stored correctly.
  • Freeze-thaw cycles: Limit to a maximum of 2–3 freeze-thaw cycles. Each cycle may result in measurable loss of enzymatic activity.
  • Avoid: Repeated warming, exposure to detergents (unless specified in the assay protocol), and storage at -20 °C for prolonged periods, as frost-free freezers undergo temperature fluctuations that can damage protein structure.
  • Working solutions: Prepare working dilutions fresh on the day of the experiment using a compatible assay buffer.

Stability data specific to this product lot are provided on the CoA. Review flags have been noted for any numerical stability claims not confirmed by lot-specific data.

Functional Application: Na+/K+-ATPase Activity Assay

Recombinant Human ATP1A2 Protein is suitable for use in in vitro Na+/K+-ATPase enzymatic activity assays. The following general procedure is recommended as a starting point; optimization may be required for specific experimental setups:

  1. Assay buffer preparation: Prepare a reaction buffer containing NaCl (100–140 mM), KCl (10–20 mM), MgCl₂ (3–5 mM), and Tris-HCl (20–50 mM, pH 7.4). Adjust ion concentrations as needed based on assay objectives.
  2. Protein dilution: Dilute the recombinant ATP1A2 protein to the desired working concentration in assay buffer. Perform a preliminary dose-response experiment to determine the optimal protein concentration for your assay format.
  3. Reaction initiation: Initiate the reaction by adding ATP (typically 1–5 mM) to the protein-buffer mixture. Incubate at 37 °C for the desired time period (commonly 30–60 minutes).
  4. Phosphate detection: Measure inorganic phosphate (Pi) release as a readout of ATPase activity using a colorimetric phosphate detection reagent (e.g., malachite green phosphate assay or molybdate-based assay).
  5. Controls: Include a no-protein blank, a heat-inactivated protein negative control, and, where applicable, a ouabain-treated sample (Na+/K+-ATPase-specific inhibitor) to confirm signal specificity.

Specific activity values and recommended assay conditions for this product lot should be referenced from the CoA. Assay parameters provided here are general guidelines derived from standard biochemical practice.

Troubleshooting Common Issues

If unexpected results are observed when working with Recombinant Human ATP1A2 Protein, consider the following troubleshooting steps:

IssuePossible CauseSuggested Resolution
No detectable ATPase activityProtein denatured due to improper storage or excessive freeze-thaw cyclesUse a freshly prepared aliquot; confirm storage conditions; check protein integrity by SDS-PAGE
High background signal in assayContaminating phosphatases or ATPases in buffer componentsUse fresh, high-purity reagents; include ouabain control to distinguish non-specific signal
Protein aggregation after reconstitutionReconstitution buffer incompatibility or rapid temperature changeAllow vial to fully equilibrate before reconstitution; add BSA as carrier; centrifuge and use supernatant
Inconsistent results between experimentsVariability from multiple freeze-thaw cycles or inconsistent working concentrationsPre-aliquot protein into single-use volumes; standardize dilution protocol; verify concentration by A280 or BCA assay

Frequently asked questions

What is the recommended reconstitution buffer for Recombinant Human ATP1A2 Protein?

The reconstitution buffer recommendation is provided on the Certificate of Analysis (CoA) for each specific product lot. In general, sterile ultrapure water or PBS (pH 7.4) supplemented with 0.1% BSA is commonly used for recombinant proteins to maintain stability. Always consult the CoA accompanying your specific vial for lot-specific guidance.

How should I store Recombinant Human ATP1A2 Protein to preserve enzymatic activity?

For long-term storage, aliquot the reconstituted protein and store at -80 °C. For short-term use within one week, storage at 4 °C is acceptable. Limit freeze-thaw cycles to no more than 2–3 times, as repeated cycling degrades enzymatic activity. Avoid storage in frost-free freezers at -20 °C due to temperature fluctuations.

Which inhibitor can I use as a specificity control in Na+/K+-ATPase activity assays with ATP1A2?

Ouabain (a cardiac glycoside) is the classical and most widely used specific inhibitor of Na+/K+-ATPase, including the alpha-2 isoform. Including an ouabain-treated sample as a negative control allows you to distinguish ATP1A2-specific ATPase activity from background phosphate release by other phosphatases or ATPases present in the reaction.

Is Recombinant Human ATP1A2 Protein suitable for use in drug screening assays?

Yes, Recombinant Human ATP1A2 Protein can be used as a target in in vitro drug screening assays, particularly for identifying inhibitors or modulators of Na+/K+-ATPase alpha-2 subunit activity. Its relevance to Familial Hemiplegic Migraine type 2 and cardiac conditions makes it a valuable tool for therapeutic compound screening. Optimization of assay conditions for high-throughput formats may be required.

References

  1. Blanco G, Mercer RW. Isozymes of the Na-K-ATPase: heterogeneity in structure, diversity in function. Am J Physiol. 1998;275(5):F633-F650. PMID:9815123
  2. De Fusco M, et al. Haploinsufficiency of ATP1A2 encoding the Na+/K+ pump alpha2 subunit associated with familial hemiplegic migraine type 2. Nat Genet. 2003;33(2):192-196. doi:10.1038/ng1081
  3. Kaplan JH. Biochemistry of Na,K-ATPase. Annu Rev Biochem. 2002;71:511-535. doi:10.1146/annurev.biochem.71.102201.141218

Products are supplied for research and development use only. Not for use in humans, animals, diagnosis, or therapy.

目录: 实验方案(Protocols)

Da — 若无特别说明,分子量单位默认为道尔顿。   Mw — 重均分子量。   Mn — 数均分子量。

产品仅供科研与开发使用,不用于人体、动物、诊断或治疗。

引用本文

阿拉丁科学.《Recombinant Human ATP1A2 Protein: Handling & Usage Protocol》. 阿拉丁知识库,更新于 2026年10月27日。 https://www.aladdin-e.com/zh_cn/faqs/recombinant-human-atp1a2-protein-handling-usage-protocol-en.html
这篇文章对您有帮助吗? Yes No 有 3 人觉得有帮助